KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).
David Michael Waterhouse
No relevant relationships to disclose
Dawn Michelle Stults
No relevant relationships to disclose
Davey B. Daniel
No relevant relationships to disclose
Paula L. Griner
No relevant relationships to disclose
F Anthony Greco
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose
David R. Spigel
No relevant relationships to disclose